Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    ZN-C3

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 393,691Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zentalis Reports Azenosertib Activity In Cyclin E1+ Ovarian Cancer
    Zentalis Reports Azenosertib Activity In Cyclin E1+ Ovarian Cancer

    29 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/29/3017038/0/en/Zentalis-Pharmaceuticals-Shares-Updated-Clinical-Data-Demonstrating-Meaningful-Azenosertib-Activity-in-Cyclin-E1-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    29 Jan 2025
    Share Share
    Zentalis Pharmaceuticals Restructures To Support Azenosertib
    Zentalis Pharmaceuticals Restructures To Support Azenosertib

    28 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/28/3016757/0/en/Zentalis-Pharmaceuticals-Announces-Strategic-Restructuring-to-Support-Late-Stage-Azenosertib-Development.html

    GLOBENEWSWIRE
    28 Jan 2025
    Share Share
    Zentalis Gains Fast Track for Azenosertib & Hosts Corporate Event
    Zentalis Gains Fast Track for Azenosertib & Hosts Corporate Event

    09 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/09/3006950/0/en/Zentalis-Pharmaceuticals-Announces-Azenosertib-Fast-Track-Designation-and-Virtual-Corporate-Event-to-Present-Updated-Data-from-Azenosertib-Clinical-Studies.html

    GLOBENEWSWIRE
    09 Jan 2025
    Share Share
    Zentalis Pharma to Present Preclinical Azenosertib Data at ESMO 2024
    Zentalis Pharma to Present Preclinical Azenosertib Data at ESMO 2024

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942660/0/en/Zentalis-Pharmaceuticals-to-Present-Preclinical-Azenosertib-Data-at-ESMO-2024.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies,Patient Deaths
    Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies,Patient Deaths

    19 Jun 2024

    // BIOSPACE

    https://www.biospace.com/article/zentalis-hit-with-fda-partial-clinical-hold-on-three-cancer-studies-following-two-patient-deaths-/

    BIOSPACE
    19 Jun 2024
    Share Share
    Zentalis Pharmaceuticals Q1 2024 Results And Operational Progress
    Zentalis Pharmaceuticals Q1 2024 Results And Operational Progress

    07 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/07/2876560/0/en/Zentalis-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Operational-Progress.html

    GLOBENEWSWIRE
    07 May 2024
    Share Share